Keryx Biopharmaceuticals Announces Trade Name Auryxia(TM)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Keryx Biopharmaceuticals Announces Trade Name Auryxia(TM) for Ferric Citrate

NEW YORK, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) (the "Company"), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the trade name Auryxia™ (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are excited to receive FDA approval of the trade name Auryxia. We look forward to launching Auryxia in the U.S. at year end and to providing nephrologists with an effective phosphate binder for dialysis-dependent CKD patients."

For more information about Auryxia, please visit www.Auryxia.com .

About End Stage Renal Disease (ESRD) and Hyperphosphatemia

In the United States, there are currently more than 400,000 ESRD patients that require dialysis, with the number projected to rise in the future. Managing ESRD is complex as many metabolic factors, such as iron and phosphorus, are out of balance. Phosphate retention and the resulting hyperphosphatemia in dialysis patients are typically associated with increased risk for heart and bone disease, and death. The majority of ESRD patients require chronic treatment with phosphate-binding agents to lower and maintain serum phosphorus at acceptable levels. In addition, iron can be severely depleted in dialysis patients and they therefore are often treated with intravenous iron and other medications.

About Auryxia™ (ferric citrate)

Auryxia™ (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The U.S. approval of Auryxia was based on data from the Company's Phase 3 registration program. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 to 5.5 mg/dL.

The ferric iron component of Auryxia binds with dietary phosphate in the GI tract, and precipitates as ferric phosphate. The unbound ferric iron in Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT), whereas these parameters remained relatively constant in patients treated with active control (Renvela® and/or Phoslo®). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, vomiting and constipation.

For more information about Auryxia, visit www.Auryxia.com . For Full Prescribing Information for Auryxia, please visit http://keryx.com/wp-content/uploads/Auryxia_P...112014.pdf .

Auryxia™ (ferric citrate) Important Safety Information

Contraindication:  Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia™ (ferric citrate).

Iron Overload:  Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy.

Accidental Overdose of Iron:  Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age . Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child.

Patients with Gastrointestinal Bleeding or Inflammation:  Safety has not been established for these patients.

Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%) .  Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%).

Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron.

Drug Interactions:  Doxycycline should be taken at least 1 hour before Auryxia. 

For Full Prescribing Information for Auryxia, please visit http://keryx.com/wp-content/uploads/Auryxia_P...112014.pdf .

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, headquartered in New York, is focused on bringing innovative therapies to market for patients with renal disease. The Company's FDA-approved product, Auryxia, is indicated in the United States for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. Keryx plans to commercially launch Auryxia in the U.S. at year end. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona ® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. 

Cautionary Statement

Some of the statements included in this press release, particularly those regarding the commercialization and subsequent clinical development of Auryxia, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether Auryxia will be successfully launched and marketed in the U.S.; whether Riona® will be successfully marketed by our Japanese partner, Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd; the risk that the EMA may not concur with our interpretation of our Phase 3 study results, supportive data, conduct of the studies, or any other part of our MAA submission and could ultimately deny approval of the MAA; the risk that we may not be successful in the development of ferric citrate for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com . The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT: Amy Sullivan, Vice President - Corporate Development and Public Affairs Keryx Biopharmaceuticals, Inc. Tel: 617.466.3447 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 25

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 120

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 43

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 52

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Customer Care: Apivia and SoundHound Unite

Updated Category News Views 247

Transforming Customer Service with AI SoundHound AI (NASDAQ: SOUN) has joined forces with Apivia Courtage, a notable entity within France's AEMA Group, which is recognized as a leading mutual insurance organization. This partnership aims to implement agent-based artificial intelligence into Apivia Courtage's customer service systems through the innovative Amelia 7...

Continue Reading
Taiwan's Bold Pedal Into Sustainability: EUROBIKE 2026

Updated Category News Views 40

Stepping Up the Game at EUROBIKE 2026 Ask any veteran cyclist: The road to innovation is a winding one, and Taiwan's Bicycle Industry seems determined to tackle every curve head-on at EUROBIKE 2026. This isn't just about flashy tech; it's a full-blown commitment to smart, low-carbon mobility—a real 'get on the bike or get left behind' moment. Unveiling the AI-Powered...

Continue Reading
TDI Welcomes Jay Truesdale as New Chief Executive Officer

Updated Category News Views 389

TD International Appoints New Leadership TD International LLC (TDI), a prominent strategic advisory and risk intelligence firm, has announced significant leadership changes with the appointment of Jay Truesdale as Chief Executive Officer. This move marks a pivotal moment for TDI, as it looks to leverage Truesdale's considerable expertise in geopolitics and global markets....

Continue Reading
Canaan Inc. Streamlines Focus on Core Cryptocurrency Market

Updated Category News Views 258

Canaan Inc. Streamlines Focus on Core Cryptocurrency Market Canaan Inc. (NASDAQ: CAN) has recently taken a significant step in refining its business operations. The company is discontinuing its non-core AI semiconductor division to concentrate on its core strengths in the ever-evolving world of cryptocurrency. This strategic decision is aimed at enhancing efficiencies and...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 567

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading